When cancer that begins in the stomach or other parts of the gastrointestinal tract spreads to distant organs such as the liver, lungs, or lymph nodes, doctors face the critical challenge of accurate and timely diagnosis to guide treatment decisions and improve quality of life for patients.

Introduction: Who Should Undergo Diagnostics and When

Metastatic gastrointestinal cancer refers to cancer that has spread from its original location in the digestive system to other parts of the body. The term metastatic describes cancer cells that have traveled through the bloodstream or lymphatic system to form new tumors in distant organs. This advanced form of cancer requires specific diagnostic approaches to determine the extent of spread and guide treatment planning.^[1]

Early diagnosis of metastatic gastrointestinal cancer is of vital importance, as it may lead to substantial elongation of life expectancy. Unfortunately, many patients with gastrointestinal cancers are diagnosed at advanced stages due to subtle symptoms in earlier disease and low rates of regular screening. The common target sites for metastasis include the liver, lymph nodes, the tissue lining the abdominal cavity (called the peritoneum), and subsequently the lungs and other sites of the body. When these metastases occur either singly or together, they become the major cause of gastrointestinal cancer-related deaths.^[1][3]

People who should seek diagnostic testing include those experiencing concerning symptoms related to their digestive system. These symptoms can include persistent indigestion or heartburn, abdominal bloating, nausea, loss of appetite, blood in the stool, vomiting, unexplained weight loss, abdominal pain, yellowing of the eyes or skin (jaundice), fluid buildup in the abdomen, problems swallowing, or persistent fatigue. Additionally, individuals with risk factors such as a family history of gastrointestinal cancers, previous diagnosis of precancerous conditions, or exposure to known risk factors should consider regular screening even without symptoms.^[2][5]

When cancer is advanced at first diagnosis, or when it has come back and spread after treatment for the original cancer, comprehensive diagnostic testing becomes essential. The timing of diagnostic tests matters significantly because metastatic gastrointestinal cancer often progresses rapidly, and associated complications such as malnutrition can have a significant impact on the patient’s quality of life and ability to tolerate treatment. Therefore, seeking medical attention promptly when symptoms appear is crucial for optimal management.^[3][18]

Diagnostic Methods for Identifying Metastatic Gastrointestinal Cancer

Physical Examination and Medical History

The diagnostic process typically begins with a comprehensive physical examination and review of medical history. During the physical exam, doctors feel for masses or anything unusual in the abdomen and other areas. They examine the patient’s overall health status and look for signs such as jaundice, fluid accumulation in the abdomen, or swollen lymph nodes. The medical history review includes discussion of symptoms, family history of cancer, lifestyle factors, and any previous medical conditions or treatments.^[5][11]

Blood Tests

Blood tests play an important role in the diagnostic workup of metastatic gastrointestinal cancer. A complete blood count can reveal anemia, which may result from chronic bleeding in the digestive tract. Blood tests can also assess liver function, kidney function, and overall nutritional status. Additionally, doctors may order tests to measure certain substances in the blood that could indicate the presence of cancer or help monitor treatment response.^[5]

Upper Endoscopy

Upper endoscopy, also called esophagogastroduodenoscopy or EGD, is a procedure that allows doctors to examine the inside of the esophagus, stomach, and the first part of the small intestine. During this test, a thin, flexible tube with a light and camera on the end is passed through the mouth and down into the digestive tract. This procedure enables direct visualization of any abnormal areas, and doctors can take small tissue samples (biopsies) for laboratory analysis. Upper endoscopy is particularly valuable for diagnosing stomach cancer and determining whether it has spread to nearby structures.^[5][11]

Colonoscopy and Sigmoidoscopy

For cancers originating in the colon or rectum, colonoscopy and sigmoidoscopy are essential diagnostic tools. A colonoscopy examines the entire large intestine using a long, flexible tube with a camera. During the procedure, the tube is inserted through the anus to view the inside of the large bowel. This helps diagnose or treat certain medical conditions affecting the colon and rectum. Sigmoidoscopy examines only the lower portion of the colon. Both procedures allow doctors to identify tumors, take biopsies, and assess the extent of disease in the lower digestive tract.^[5]

Imaging Studies

Various imaging tests are crucial for determining whether gastrointestinal cancer has spread to other parts of the body. Computed tomography (CT) scans create detailed, three-dimensional images of the body using X-rays taken from multiple angles. CT scans of the chest, abdomen, and pelvis can reveal metastases in the liver, lungs, lymph nodes, and other organs. These scans are particularly useful for treatment planning and monitoring response to therapy.^[4][5]

Positron emission tomography (PET) scans use a small amount of radioactive sugar to identify areas of high metabolic activity, which often indicates cancer. PET scans can detect metastatic disease throughout the body and are sometimes combined with CT scans (PET-CT) to provide both functional and anatomical information in a single test. This combined approach helps doctors distinguish between benign and malignant findings more accurately.^[4]

Ultrasound uses sound waves to create images of internal organs and is particularly useful for examining the liver and abdominal cavity. Pelvic and transvaginal ultrasound can help detect spread to reproductive organs in women. Ultrasound is also used during certain biopsy procedures to guide the needle to the exact location of concern.^[5]

Magnetic resonance imaging (MRI) uses powerful magnets and radio waves to create detailed images of soft tissues. MRI is especially helpful for evaluating the brain, spine, and liver for metastatic disease. It provides excellent contrast between different types of tissues and can detect small metastases that might be missed by other imaging methods.^[4]

Biopsy Procedures

A biopsy involves removing a small sample of tissue for examination under a microscope. This is the definitive way to confirm whether cancer cells are present and to determine their characteristics. For metastatic gastrointestinal cancer, biopsies can be obtained from the primary tumor in the digestive tract or from suspected metastatic sites. The tissue samples are analyzed by pathologists who can identify the type of cancer cells and provide information about their origin and characteristics.^[4][5]

When cancer cells are examined under a microscope and tested, metastatic cancer cells have features similar to those of the primary cancer rather than the cells normally found in the location where the metastasis developed. This is how doctors can determine that cancer has spread from another part of the body. For example, stomach cancer that has spread to the liver will still look like stomach cancer cells under the microscope, not liver cancer cells.^[4]

Staging and Classification

Once cancer is diagnosed, doctors use a staging system to describe how much cancer is present and where it has spread. The most common staging system uses the TNM classification, which stands for Tumor, Node, and Metastasis. This system evaluates the size and extent of the primary tumor, whether cancer has spread to nearby lymph nodes, and whether distant metastasis has occurred. Advanced or metastatic gastrointestinal cancer is typically classified as stage 4, indicating that cancer has spread to distant organs or tissues.^[7]

The staging process helps doctors determine the most appropriate treatment approach and provides information about prognosis. Generally, the higher the stage number, the more the cancer has spread. Understanding the stage of cancer is crucial for making informed decisions about treatment options and expected outcomes.^[7]

Diagnostics for Clinical Trial Qualification

Molecular and Genetic Testing

Modern approaches to treating metastatic gastrointestinal cancer increasingly rely on understanding the molecular and genetic characteristics of individual tumors. Classification based on molecular biomarkers provides an opportunity to differentiate patients who may benefit from specific targeted therapies or immunotherapy. Several key biomarkers are routinely tested in patients being considered for clinical trials or specialized treatments.^[12]

Human epidermal growth factor receptor 2 (HER2) testing is essential for patients with metastatic stomach or gastroesophageal junction cancer. HER2 is a protein that, when overexpressed, can drive cancer growth. Testing for HER2 status helps identify patients who might benefit from targeted therapies directed against this protein. The evaluation of HER2 status should be considered in all patients with metastatic gastroesophageal adenocarcinoma, as HER2-positive status opens up additional treatment options.^[9][12]

Programmed cell death ligand 1 (PD-L1) testing measures the expression of a protein that cancer cells sometimes use to evade the immune system. Patients whose tumors express high levels of PD-L1 may be candidates for immunotherapy treatments that help the immune system recognize and attack cancer cells. This testing is particularly important for determining eligibility for certain clinical trials and approved immunotherapy regimens.^[9][12]

Microsatellite instability (MSI) testing identifies tumors with defects in DNA repair mechanisms. Tumors classified as MSI-high or having deficient mismatch repair (dMMR) often respond well to immunotherapy. Clinical trials have demonstrated impressive efficacy and prolonged survival in patients with MSI-high or dMMR metastatic gastrointestinal cancer treated with immune checkpoint inhibitors. Therefore, MSI testing has become a standard part of the diagnostic workup for metastatic disease.^[12]

Performance Status Assessment

Clinical trials typically require assessment of a patient’s overall functional status and ability to perform daily activities. This evaluation, called performance status, helps determine whether a patient is healthy enough to tolerate experimental treatments. Various scoring systems are used to rate performance status, and these measurements are often part of the eligibility criteria for clinical trial enrollment. Performance status assessment considers factors such as the patient’s ability to work, carry out normal activities, and care for themselves.^[18]

Specialized Laboratory Tests

Participation in clinical trials may require additional specialized laboratory tests beyond routine blood work. These can include detailed kidney and liver function tests, cardiac function assessment through electrocardiograms or echocardiograms, and comprehensive metabolic panels. Some trials also require testing for specific genetic mutations or protein expressions that are targets of investigational drugs.^[12]

Nutritional assessment is particularly important in patients with metastatic gastrointestinal cancer, as malnutrition is common and can significantly impact treatment tolerance and outcomes. Clinical trials often include evaluation of nutritional status, weight trends, and albumin levels as part of their eligibility criteria and ongoing monitoring.^[18]

Imaging Requirements for Trial Entry

Clinical trials often have specific imaging requirements both for initial enrollment and for monitoring treatment response. Baseline imaging studies, typically including CT or PET-CT scans, are performed to document the extent of metastatic disease before treatment begins. These scans serve as reference points for comparing future images to assess whether treatment is working. Some trials require imaging at specified intervals throughout the treatment period to track changes in tumor size and the appearance of new metastases.^[12]

The measurements obtained from these imaging studies help researchers determine response rates and progression-free survival, which are important endpoints in evaluating new treatments. Standardized criteria are used to assess tumor response, including complete response (disappearance of all tumors), partial response (significant shrinkage), stable disease (no significant change), and progressive disease (growth or new metastases).^[12]